Trial results

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

NCT07415954 on ClinicalTrials.gov · last registry update 2026-08-10

An unusually large phase 2: 270 participants, more than double the 114 typical for the stage. Due to report 3 September 2027, alongside 39 other tracked readouts that quarter. Primary outcome, as filed: Change in glycated haemoglobin (HbA1c) (week 16). Sponsors move these dates routinely; any movement since this site started watching is listed below. semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

RECRUITING

Phase

P2

Drug

semaglutide

Rybelsus, Wegovy, Ozempic

Sponsor

Novo Nordisk A/S

Sponsor type

Industry

Enrollment

270

Started

2026-04-17

Primary completion

2027-09-03 estimated

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in glycated haemoglobin (HbA1c) (week 16)

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.